Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

G. Caocci, O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, N. Sgherza, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M.M. Trawinska, F. De Gregorio, D. CattaneoF. Albano, G. Gugliotta, C. Baratè, L. Scaffidi, C. Elena, F. Pirillo, E. Scalzulli, G. La Nasa, R. Foà, M. Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalHematological Oncology
Volume37
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • arterial occlusive event
  • chronic myeloid leukemia
  • ponatinib
  • prophylaxis
  • acetylsalicylic acid
  • imidazole derivative
  • pyridazine derivative
  • adult
  • aged
  • cardiology
  • clinical decision support system
  • clinical trial
  • complication
  • coronary artery occlusion
  • epidemiology
  • female
  • human
  • hypertension
  • incidence
  • Italy
  • male
  • middle aged
  • multicenter study
  • oncology
  • procedures
  • retrospective study
  • risk factor
  • treatment outcome
  • very elderly
  • young adult
  • Adult
  • Aged
  • Aged, 80 and over
  • Aspirin
  • Cardiology
  • Coronary Occlusion
  • Decision Support Systems, Clinical
  • Female
  • Humans
  • Hypertension
  • Imidazoles
  • Incidence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Medical Oncology
  • Middle Aged
  • Pyridazines
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome
  • Young Adult

Cite this

Caocci, G., Mulas, O., Abruzzese, E., Luciano, L., Iurlo, A., Attolico, I., Castagnetti, F., Galimberti, S., Sgherza, N., Bonifacio, M., Annunziata, M., Gozzini, A., Orlandi, E. M., Stagno, F., Binotto, G., Pregno, P., Fozza, C., Trawinska, M. M., De Gregorio, F., ... Breccia, M. (2019). Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 37(3), 296-302. https://doi.org/10.1002/hon.2606